Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SFA 001

Next Previous
Search
Drug Profile

SFA 001

Alternative Names: SFA-001; SFA-001N

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Temple University
  • Developer SFA Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; G-protein coupled receptor 43 modulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Research Fibrosis
  • No development reported Liver cancer; Non-alcoholic steatohepatitis
  • Discontinued Hepatitis B

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for preclinical development in Liver-cancer in USA (PO)
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
  • 22 Oct 2024 SFA Therapeutics has patent protection for SFA 001 in USA and South Korea

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top